Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models
Science Translational Medicine · 01.07.2026 · 18 (856)
DOI: 10.1126/scitranslmed.aea9877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 01.07.2026. Verfasst von Niharika Shiva und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Hauptthemen laut MEDLINE: Ventricular Remodeling, Receptors, Neurotensin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: NIDDK NIH HHS, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The neuropeptide neurotensin (NTS) is up-regulated in cardiac lymphatic endothelial cells (LECs) in response to ischemic or mechanical damage, but its role in cardiac remodeling is unknown. Here, we aimed to define the role of LEC-derived NTS in cardiac injury responses and to assess the therapeutic potential of targeting cardiac NTS signaling. In cultured murine and human cells, NTS reduced cardiomyocyte hypertrophy and fibroblast activation, and these effects were mediated by NTS receptor 2 (NTSR2)–dependent guanosine 3′,5′-monophosphate (cGMP) production. Consistent with an antihypertrophic and antifibrotic role of NTS, mice with LEC-specific Nts deletion exhibited aggravated hypertrophy and fibrosis after transverse aortic constriction (TAC) and myocardial infarction (MI). Similarly, cardiomyocyte-specific or activated fibroblast-specific inactivation of Ntsr2 led to enhanced cardiac remodeling after TAC. NTSR2 agonist NT150 reproduced the beneficial effects of NTS in cultured human and murine cells and ameliorated cardiac remodeling and dysfunction in both TAC and MI. Additionally, in freshly isolated cardiac tissues from patients with heart failure, NT150 induced cGMP production and suppressed prohypertrophic signaling. These findings identify NTS as an endogenous inhibitor of adverse cardiac remodeling and suggest NTSR2 agonism as a therapeutic strategy in heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
- Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.
- Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen, Germany.
- Circadian Regulation of Cardiometabolism Lab, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Frankfurt am Main, Germany.
- Cardiopulmonary Institute, Goethe University, Frankfurt am Main, Germany.
ORCID-Profile: Niharika Shiva, Haruya Kawase, Jürgen Einsiedel, Jeonghyeon Kwon, Jingchen Shao, Stefan Günther, Pieterjan Dierickx, Samuel Sossalla, Stefan Offermanns, Peter Gmeiner, Nina Wettschureck
Förderung
- NIDDK NIH HHS
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Shiva, N., Kawase, H., Einsiedel, J., Kwon, J., Kumar, S., Shao, J., Du, Z., Kubin, N., Shimari, M., Günther, S., Li, T., Dierickx, P., Sossalla, S., Offermanns, S., Gmeiner, P., & Wettschureck, N. (2026). Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models. Science Translational Medicine, 18(856). https://doi.org/10.1126/scitranslmed.aea9877
Vancouver
Shiva N, Kawase H, Einsiedel J, Kwon J, Kumar S, Shao J, et al. Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models. Science Translational Medicine. 2026;18(856). doi:10.1126/scitranslmed.aea9877
BibTeX
@article{Shiva2026,
author = {Shiva, Niharika and Kawase, Haruya and Einsiedel, Jürgen and Kwon, Jeonghyeon and Kumar, Shamit and Shao, Jingchen and Du, Zhaoyu and Kubin, Natalia and Shimari, Miho and Günther, Stefan and Li, Tiangang and Dierickx, Pieterjan and Sossalla, Samuel and Offermanns, Stefan and Gmeiner, Peter and Wettschureck, Nina},
title = {Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {856},
doi = {10.1126/scitranslmed.aea9877}
}
EUVIMED